

Prospective Australasian National Bifurcation Coronary Intervention Outcomes Registry

ACTRN12624000143527

Status	RECRUITING
Sponsor	Northern Sydney Local Health District
Enrollment	1,750 participants

Plain Language Summary

This study is building a detailed registry to track how blocked coronary artery bifurcations — points where a heart artery splits into two branches — are treated across Australia and New Zealand. When plaque builds up at these junctions, it creates one of the trickier challenges in heart stenting procedures, and there is currently no shared database recording what techniques are used and how patients fare afterward.

The registry is observational only, meaning doctors will continue treating patients exactly as they normally would. The study simply records what was done and follows up on outcomes at 72 hours, 3 months, 1 year, and 2 years to understand which approaches work best in real-world practice.

You may be eligible if you are 18 or older and have significant blockage (70% or more) in a bifurcation artery, or if that artery is the culprit in a heart attack. You must be treated with drug-eluting stents. People in cardiogenic shock, with active bleeding disorders, or with allergy to antiplatelet medications are not eligible.

Key Eligibility Criteria

Inclusion (6)

- years and older.
- Coronary bifurcation according to the Medina classification of bifurcations (1,1,1; 1,0,0; 1,1,0; 1,0,1; 0,1,1; 0,1,0).
- Main branch diameter greater than or equal to 2.5mm and side branch diameter greater than or equal to 2mm.
- Lesion severity greater than or equal to 70% stenosis, positive pressure wire assessment (FFR less than or equal to 0.8; iFR<0.9), culprit lesion for ST-elevation myocardial infarction (STEMI) or Non-STEMI (NSTEMI), or positive functional assessment in the territory being revascularized.
- Treated with either a provisional or 2 stent strategy.

... and 1 more (see full listing online)

Exclusion (5)

- Age less than 18 years
- Cardiogenic Shock
- Allergy/intolerance to anti-platelet medication
- Less than 1 year expected survival
- Active bleeding disorder

Locations (1 total)

New Zealand

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000143527>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.